Compounded GLP-1s in 2026 — what changed and what to ask

I get this question almost weekly: “My telehealth provider switched me from compounded semaglutide to compounded tirzepatide, but the dose and schedule are different from what I had before. Is that normal?”

The answer in 2026 is more complicated than it was in 2024. The compounded-GLP-1 market has shifted significantly, and the version of the conversation a patient was having a year ago doesn’t quite map onto what’s available now.

If you’re on compounded GLP-1s, on a brand med that’s hard to fill, or thinking about switching — here’s a snapshot of where things stood as of early 2026, and the questions worth bringing to your prescriber.

Quick recap on how compounding got here

In 2022-2024, both semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) were declared by the FDA to be in shortage. That status legally authorized 503A and 503B compounding pharmacies to produce versions of these molecules — usually at lower cost — to meet the gap.

Telehealth-driven cash-pay programs grew rapidly in that window. By late 2024, somewhere between 1.5 and 2 million people in the U.S. were on compounded GLP-1s outside the brand supply chain.

Then the shortage status started lifting:

October 2024: FDA removed tirzepatide from the shortage list, with a transition period for compounders to wind down.
Early 2025: FDA took similar action for semaglutide. Compounding under shortage authority was no longer permitted by the deadline.

By 2026, compounded GLP-1s are still legally available — but only under narrower indications:

As personalized medications prepared for a specific patient with documented clinical need (e.g., a true allergy or sensitivity to an ingredient in the brand product, or a dose strength not commercially manufactured).
As alternative formulations that aren’t simply copies of the brand drug. This is the vector under which most surviving compounded products operate — typically as combination products (e.g., semaglutide + B12, semaglutide + cyanocobalamin) at non-standard concentrations.

The “I just want it cheaper” pathway that drove most of the 2023-2024 compounded volume is no longer available the way it was. Patients who were on cash-pay compounded programs at $200-300/month often saw their providers either switch them to a combination formulation, transition them to brand product (now more available, though insurance coverage varies), or sunset the prescription.

What that means for patients in early 2026

If you’re currently on compounded semaglutide or tirzepatide, the situation depends on your specific provider and pharmacy:

You may be on a combination product. Many compounding pharmacies pivoted to combination formulations to maintain legal footing. These look like “semaglutide/B12” or “tirzepatide/levocarnitine” on your label. The GLP-1 dose is usually the active driver of effect; the other ingredients may or may not contribute meaningful action depending on the formulation.

Your dose may not match brand-product strengths. Brand semaglutide comes in fixed steps: 0.25, 0.5, 1.0, 1.7, 2.4 mg/week (Wegovy) or 0.25, 0.5, 1.0, 2.0 (Ozempic). Compounded products often come in custom strengths, sometimes denominated in concentrations (e.g., 5 mg/mL) where the dose drawn from the vial determines the effective weekly mg. Make sure you understand your delivered mg/week, not just the vial concentration.

Your provider should still be titrating you. GLP-1 dose escalation is dose-dependent, regardless of whether the product is brand or compounded. The standard pattern (4 weeks at 0.25, 4 weeks at 0.5, escalate as tolerated) was developed for brand products but applies clinically. If your prescriber jumped you from 0.25 to 1.0 in two weeks because “the supply changed,” that’s a clinical question worth raising.

The four questions to ask your prescriber

If you’re on a compounded GLP-1 right now, here’s what I’d want answered if I were you:

1. What’s my actual delivered weekly dose?

Not the vial concentration. Not the syringe units. The weekly mg of GLP-1 active ingredient you’re absorbing. If your pharmacy ships a 5 mg/mL vial and you’re drawing 0.1 mL weekly, that’s 0.5 mg/week. Make sure you and your prescriber agree on this number, because dose miscommunication is the most common failure mode I see.

2. Are you using the brand titration schedule or a custom one?

If custom, why? Faster escalation than brand may save weeks of low-dose time but typically increases GI side effects. Slower may help tolerance but extend the time to therapeutic dose. Either is defensible — but you should know which you’re on.

3. What happens if my supply gets cut off?

Compounded supply has been less stable than brand supply. If your pharmacy stops making your formulation (which has happened to several mid-tier compounders this year), what’s the transition plan? Brand product? A different compounded option? Tapered discontinuation? Get the answer before you need it.

4. Is there a path to brand coverage I haven’t tried?

Brand availability has improved substantially since 2024. Insurance coverage varies wildly by plan, but many patients on cash-pay compounded programs in 2024-2025 are now eligible for partial or full coverage of brand product through their insurance plan in 2026. A prior auth or formulary appeal is worth attempting at least once a year, or on plan changes.

What I tell my own patients on compounded GLP-1s

A few things I emphasize regardless of which formulation someone is on:

Track the side effects week by week. GI symptoms (nausea, reflux, slowed digestion) are the most common, and they should plateau or improve over 6-8 weeks at a stable dose. Worsening symptoms after dose stability is a red flag worth raising.
Eat enough protein. GLP-1 effects on appetite reduce intake substantially, and protein is the macro most often shorted on compounded GLP-1 patients. Aim for 0.8-1.0 g per pound of target bodyweight, not current. Inadequate protein on GLP-1 = accelerated lean mass loss = slower long-term metabolic outcomes.
Don’t compare yourself to brand-trial outcomes. Wegovy STEP trials and Zepbound SURMOUNT trials produced specific weight-loss percentages on specific titration protocols. Compounded protocols vary; your outcome variance is wider. Don’t measure against the trial average.
Take provenance seriously on the compounded side. Not all 503A pharmacies have the same quality controls. Ask your prescriber whether they’ve personally vetted the pharmacy or whether they’re going by a referral. The recent cluster of FDA letters to non-compliant compounders is worth reviewing if you’re curious.

What’s coming in 2026

A few things to watch over the rest of the year:

Generic semaglutide. Patent cliffs in some markets are approaching. The U.S. market won’t see generic semaglutide in 2026 (composition-of-matter patents extend to 2031), but pricing pressure on brand may continue as international generic supply expands.
Oral GLP-1s. Several oral formulations are in late-stage trials. Brand availability of an oral high-dose semaglutide may shift the conversation away from compounded injectables for some patients.
Coverage expansion under specific employers/insurers. Several large employers added GLP-1 coverage for obesity (not just diabetes) in 2025-2026. If your employer changed plans recently, re-check coverage.

The compounded GLP-1 market in early 2026 is a different beast than it was in 2024. Patients aren’t necessarily worse off — many have transitioned to brand or to compliant combination formulations — but the conversation with your prescriber needs to be more specific about dose, titration, and continuity-of-supply than it used to be. Bring those four questions to your next visit.

Macroline is not medical advice. GLP-1 therapy decisions should be made with your prescribing clinician, who has access to your full medical history.